21 April 2020 -
SHS appoints Sascha Alilovic as Managing Partner
On April 1, 2020, Sascha Alilovic (46) was appointed Managing Partner of SHS Gesellschaft für Beteiligungsmanagement. Whether by way of succession arrangements or growth financing, SHS specializes in investing in innovative healthcare companies with a focus on medical technology and life sciences. Through several funds, SHS has more than EUR 300 million under management. It has invested in more than 60 companies since it was established in 1993. SHS is currently investing from its fifth fund generation.
Following a degree in business administration and computer science, Sascha Alilovic worked for an American-European investor and oversaw a number of investments in and exits from private tech and life sciences companies, including through IPOs in Europe and the USA. After establishing a now-global boutique for corporate finance focusing on mid-market transactions, he worked at a major German DAX-listed conglomerate for several years with managed transactions totalling double-digit billions of euros. He subsequently moved to Germany’s leading biotech company where, among other things, he was in charge of corporate finance and corporate development, established the company’s corporate venturing and prepared the US IPO. Since 2017, Sascha Alilovic has assisted SHS with the preparation and execution of exit transactions, as well as in fund-raising. He joined the company as a partner in 2018.
“We are delighted that we were able to appoint Sascha Alilovic as Managing Partner of SHS, where he succeeds founder Reinhilde Spatscheck,” Hubertus Leonhardt, Managing Partner of SHS, said of the appointment of the experienced manager. “His many years of successful work in the life-science industry and his experience in strategic transactions for firms in the healthcare sector make him a valuable addition to our team. Together, we want to continue with further investments to build our portfolio in the current SHS V and advance strategic partnerships for our existing portfolio.”
“SHS is the leading German investor for companies in the healthcare sector with strong growth potential. Our many years of experience, deep market awareness and outstanding management expertise in the medical technology sector make us a perfect sparring partner for firms, particularly where succession arrangements and international expansion are under consideration. Nearly no other provider in the market can look back on such a long company history and rise to the challenges that the industry has faced in the past years as we can. I am very much looking forward to continuing the collaboration,” Sascha Alilovic added.
About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tuebingen, Germany, and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. The company was founded in 1993 and has since gained extensive experience as an industry investor which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s European based investors include pension funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company invests up to €30 million in equity capital and volumes exceeding this amount are implemented with a network of co-investors. SHS is currently investing from its fifth fund which received capital commitments of more than €130 million. Further information: http://www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our newsletter!